English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Microdosing Mushrooms: What the Research Actually Shows About Psilocybin
Somewhere between the full-blown psychedelic trip and a regular Tuesday morning sits a quieter practice: microdosing. A crumb of dried mushroom — maybe a tenth of a gram — taken every few days, with no expectation of seeing the wallpaper breathe. People do it for focus. For mood. For creative work that won't unstick. For depression that hasn't budged in years. The question is whether any of it actually works, or whether we're all just very enthusiastic about placebo. The honest answer, as of 2026, is: somewhere in between, and the science is still catching up. If you're considering microdosing psilocybin — or any psychedelic — as part of your own recovery from addiction, depression, or just feeling stuck, here's what's actually known and what's still guesswork. A microdose is roughly one-tenth of a recreational dose. If a noticeable psychedelic experience kicks in around one gram of dried mushrooms, a microdose lands near 0.1 grams. Some people go even smaller. The point is that you shouldn't feel intoxicated. No visuals, no time dilation, no laughing at the ceiling. If you're tripping, you've overshot — that's a low dose, not a microdose. Psilocybin, the active compound in these mushrooms, gets converted in the body to psilocin, which binds to serotonin 2A receptors in the brain. At full doses, this rewiring produces the classic psychedelic experience — altered perception, dissolved ego, hallucinations, the works. At a microdose, the theory goes, you get subtle neurochemical effects without the cinematic ones: a small lift in mood, sharper attention, a looser kind of thinking. That's the theory. The evidence is messier. Here's where things get awkward. Several solid studies from the early 2020s — including placebo-controlled work that finally went beyond self-reported surveys — found that much of what people attribute to microdosing tracks closely with the placebo effect. In one widely cited trial, participants who thought they had taken a microdose reported nearly the same benefits as those who actually had. Expectation, it turns out, is a powerful drug all by itself. That doesn't mean microdosing is fake. It means we can't yet cleanly separate the chemistry from the belief. Both might be doing work. And given how much modern medicine accepts that mindset shapes outcome — see also: nearly every antidepressant trial ever — that's not nothing. It's just not the slam-dunk evidence that microdosing advocates sometimes claim. What the better studies do suggest is modest and worth taking seriously: Notice that last point. The studies showing the strongest mental-health outcomes almost all involve psychological support alongside the substance. Microdosing alone, with no therapy, no integration, no structure, gets you considerably less than microdosing inside a thoughtful framework. The mushroom isn't the treatment. The mushroom is one ingredient in the treatment. Microdosing has a reputation for being basically harmless — a sort of mushroom-flavored multivitamin. That's marketing, not science. Psilocybin remains a Schedule I substance in the U.S. and most other countries, which means unregulated supply, unknown potency, and zero quality control unless you're growing your own or sourcing from a meticulous friend. The actual reported side effects of microdosing include: And there's a bigger caution: people with a personal or family history of psychotic disorders — schizophrenia, bipolar I, schizoaffective disorder — should not microdose. Psychedelics can trigger or accelerate episodes in vulnerable people. This isn't theoretical. It's the single most important screening question a responsible facilitator will ask, and if nobody's asking you, that tells you something about who you're working with. No, and the difference matters. A retreat — whether it's psilocybin in Jamaica or the Netherlands, ayahuasca in Peru, or one of the legally sanctioned psilocybin programs now operating in Oregon and Colorado — uses a full dose in a held container with trained support. The intent is a single, intense experience that opens something up, followed by integration work to make sense of what surfaced. Microdosing is the opposite shape: subtle, repeated, woven into ordinary life. You go to work. You take a hike. You attend your kid's recital. The substance is supposed to fade into the background while quietly nudging your baseline. Some people use microdosing as preparation before a retreat or as part of integration afterward — both can make sense, though you should always check with the facilitators running your ceremony, because many traditions ask you to be substance-free for a meaningful window beforehand. If you're drawn to psilocybin because you're working through deep trauma, addiction, or treatment-resistant depression, the honest read is that a structured experience with proper support tends to do more than microdosing alone. Microdosing might help maintain gains or smooth out daily life. The heavy lifting often happens at higher doses with skilled people around you. A few practical things worth holding in mind before you decide anything: Microdosing is one small piece of a much larger conversation about psychedelics, master plants, and what we now call psychedelic-assisted recovery. The renaissance is real — clinical trials for psilocybin, MDMA, and ibogaine have produced some of the most striking results in psychiatry in decades. But the most dramatic outcomes come from full-dose, supported experiences, not from sprinkling tiny amounts into your morning coffee. If you're considering plant medicine because something in your life isn't working — addiction that won't lift, depression that grinds on, trauma that keeps replaying — it's worth thinking bigger than a microdose. A well-run psilocybin retreat, ayahuasca ceremony, or ibogaine program can do in a week what microdosing might do in a year, assuming microdosing is doing anything at all beyond placebo. For readers who want to explore the structured, supported route, a curated selection of psilocybin and plant-medicine retreats can be browsed on our marketplace here. Microdosing has its place. It's just probably not the whole answer — and anyone selling it as one is selling something other than the truth.
What DMT Actually Does: Inside the Science, the Trips, and the Healing Potential
Ask ten people who've smoked DMT to describe what happened and you'll get ten answers that all begin the same way: words don't really work for this. Then they'll try anyway. Spirals inside spirals. Beings that seemed to be waiting. A feeling of being yanked clean out of the body and dropped somewhere that felt — and this is the phrase that keeps coming up — more real than real. That phrase is doing a lot of heavy lifting, and it's worth taking seriously. DMT is the psychedelic compound at the heart of ayahuasca, the Amazonian brew that has pulled tens of thousands of seekers to jungle retreats over the past two decades. Understanding the molecule itself — what it does, where the research stands, and why people keep saying it changed their lives — is a useful piece of homework if you're weighing whether plant medicine is for you. N,N-Dimethyltryptamine is a short-acting psychedelic found across an absurd range of life. It's in hundreds of plants. It's in the venom of certain toads. It's been detected in every mammal researchers have bothered to test, including humans. We appear to make it ourselves, in small quantities, possibly in the lungs and the pineal gland. Nobody is entirely sure why. Smoked or vaporized, it produces a hallucinogenic experience that arrives within seconds and is largely over inside half an hour. Injected, similar story. Swallowed on its own, it does basically nothing — your gut breaks it down before it can reach the brain. That last fact is the whole reason ayahuasca exists. The traditional Amazonian brew combines a DMT-containing plant with a second plant that blocks the enzyme that would otherwise neutralize it, allowing the molecule to stay active for hours rather than minutes. So when people talk about ayahuasca, they're really talking about a way of taking DMT slowly, in a body that's been prepared by diet and ceremony, surrounded by people who know what to do when things get strange. DMT was first identified as psychoactive by Hungarian chemist Stephen Szára in the 1950s. A short, productive decade of research followed — including some investigations into whether endogenous DMT might explain schizophrenia (it doesn't). Then the 1970s arrived, drug laws tightened, and serious human research in the United States essentially stopped for twenty years. The thaw came in the early 1990s when psychiatrist Rick Strassman ran the first new DMT trials on humans in a generation at the University of New Mexico. His setup was deliberately bare: no incense, no statues, no guided meditation. He'd dose experienced volunteers in a hospital room and ask them to report back. The point was to see what the molecule did, stripped of expectation. What they reported was strange enough that Strassman went on to write a book about it. Volunteers described being pulled out of their bodies. Encountering entities that seemed intelligent and aware of being observed. Visiting places that didn't behave like physical space. One woman came back from her session convinced — calmly, matter-of-factly — that consciousness continues after death. If everyone knew what was waiting, everyone would commit suicide, she told him. He suggested she keep that to herself. Here's the thing that makes DMT genuinely different from other psychedelics. Mushrooms and LSD tend to modify your relationship with the world you're already in — colors smear, walls breathe, your sense of self softens. A DMT experience, by contrast, tends to feel like leaving entirely. Users describe a sensation of being launched. The geometry of ordinary space falls away and is replaced by something that operates on different rules — recursive fractals, impossible architectures, what one person I spoke with called "the back end of the simulation." Time becomes meaningless. Language follows. People often report telepathic exchanges with whatever they encounter in there, and a peculiar sense that the encounter is the point. A few recurring figures appear often enough across reports that there are entire online forums devoted to them — the jester, the mantis, the machine elves popularized by Terence McKenna. Whether these are projections of the human mind under extreme neurochemical pressure or something stranger is a question the science cannot currently answer. Probably won't anytime soon. The connection between DMT and death — or near-death — has been around long before the chemistry was understood. In Quechua, ayahuasca roughly translates to vine of the dead or vine of the souls. The traditional belief is that drinking the brew opens a doorway to the realm of disembodied spirits. The Shipibo, Shuar, and other Amazonian peoples have organized substantial portions of their cosmology and medicine around this idea for centuries. Modern interest in this overlap took off when researchers noticed that the standard near-death experience — the tunnel of light, the loving presence, the life review, the reluctance to come back — sounds an awful lot like a strong DMT trip. There's a hypothesis, still unproven, that the dying brain releases a flood of endogenous DMT as a kind of farewell. Some unpublished animal data suggests DMT levels do rise in the brain at death. It's not nothing, but it's not yet a settled case either. What we can say honestly: Whether any of that means DMT is a cosmic doorway or just an unusually interesting neurochemical, I'll let you decide. This is where things get practical for anyone reading because they're thinking about a retreat. The therapeutic conversation around DMT — and, by extension, around ayahuasca — has shifted dramatically in the last decade. Researchers have looked at ayahuasca for treatment-resistant depression, PTSD, grief, and addiction recovery. The early results are genuinely promising, particularly for people who've tried conventional treatments and come up empty. One reason DMT is hard to study clinically is that the experience is so short. Strassman and his colleague Andrew Gallimore published a paper proposing a way to deliver DMT via continuous infusion — essentially a steady IV drip that could hold someone in the state for hours rather than minutes. The reasoning is medical, not recreational: a sustained experience allows for actual therapeutic work, which is impossible to do during a fifteen-minute blast. This is also, in a sense, what ayahuasca already does. The brew stretches a DMT experience across four to six hours, long enough for emotional material to surface, be witnessed, and begin to integrate. Talk to people who've done plant medicine for trauma or addiction and you'll hear versions of the same arc: the substance shows them something they'd been avoiding, and the actual healing happens in the weeks and months afterward, in therapy, in journaling, in the slow business of changing how they live. One of Strassman's volunteers described looking back on her childhood with a clarity she'd never had sober. Another came back with strong feelings about needing to spend more time with family. A man I corresponded with — call him Sam — told me he'd been planning suicide before he tried DMT. He described the experience as the universe holding him in something that felt like oceanic love. Afterward, the cynicism that had been suffocating him simply lifted. He started living again. I include that not as a sales pitch. Plenty of people have difficult, frightening, or genuinely traumatic experiences with DMT and ayahuasca, especially when set and setting are wrong. But the testimony of people who feel they were pulled back from something terminal is consistent enough across decades and continents that it deserves to be taken seriously. Something is happening in there. A few practical points for the reader who's been Googling at midnight, weighing whether to actually do this: DMT — and ayahuasca specifically — is not for everyone, and the people running ethical retreats will tell you so. It's a powerful tool that happens to suit certain people at certain points in their lives, and it sits alongside therapy, breathwork, meditation, and a hundred other options that may serve you better depending on where you are. If after reading this you find yourself genuinely curious rather than just intellectually interested, that's worth listening to. For readers who want to take this further, a range of ayahuasca and plant medicine retreats can be browsed on our marketplace here. Take your time with the decision — the medicine, whatever you believe about it, has been around for centuries and isn't going anywhere.
Bufo Alvarius: What a 5-MeO-DMT Ceremony Actually Feels Like
Someone asked me once, very casually, over tea: “You've sat with ayahuasca, you've done kambo — but have you ever smoked the toad?” The way they said it made the question land differently. Like they were quietly checking whether I knew what I was getting into. Bufo, they kept telling me, is something else entirely. Why, I wondered, would anyone willingly sign up to feel like they're dying? And yet here I am, writing about the night I did exactly that. This is a long piece about Bufo alvarius — what the medicine is, where it comes from, what the ceremony looked like from the inside, and what stuck around afterward. If you're researching whether to sit with 5-MeO-DMT yourself, I'd rather you read an honest account than a glossy one. Bufo refers to the dried venom of the Sonoran Desert toad — Bufo alvarius, also called Incilius alvarius by the people who care about taxonomy. The toad lives in a narrow band of desert across northern Mexico and the American Southwest. Its parotid glands secrete a milky substance loaded with tryptamines, the most notable being 5-MeO-DMT, which is widely considered the most potent naturally occurring psychedelic on the planet. The secretions are harvested without killing the animal, then dried into small crystalline flakes. Those flakes get loaded into a glass pipe, gently heated, and inhaled in a single slow breath. The effects arrive almost immediately. Total duration is usually fifteen to twenty minutes by the clock. Inside the experience, time is meaningless. People come back saying it felt like forever, or like no time at all, or both. This is worth pausing on: 5-MeO-DMT is not the same as the N,N-DMT found in ayahuasca. The visual character is different. The emotional terrain is different. Ayahuasca tends to give you a narrative — scenes, memories, conversations with something that feels like an intelligence. Bufo tends to dissolve the narrator entirely. There's no story. There's just whatever is left when the story-maker stops. For a long time my answer was a polite no. The reports I heard sounded too intense, too close to actual ego death, too much like the dying I wasn't ready for. I had two kids at home. I had work I cared about. I wasn't running away from anything obvious, and I couldn't find a clean reason to invite something that felt this big. Then a stranger messaged me about a ceremony happening the following week, on the one open evening between Christmas and New Year — the only unscheduled day in a packed month. I'm not a sucker for coincidence, but my body said yes before my mind could argue. So I went. If you're considering Bufo, I'd offer this: pay attention to how the invitation arrives. Are you chasing it because you've seen testimonials on Instagram and you want what those people seemed to get? Or has it shown up in your life with a strange quiet insistence that you can't quite explain away? Those are different motivations, and they tend to produce different ceremonies. The ceremony was on the top floor of an old building near a canal in Amsterdam. Steep stairs, creaking floors, about ten of us sitting on cushions in a circle. Sage smoke. A small altar with feathers and a few stones. None of it was theatrical. It looked, honestly, like somebody's living room arranged with care. The facilitator — I'll call him Raul — opened by saying he wasn't a shaman. “We're each our own shaman,” he said. “I'm just here to sit with you while it happens.” Every actual shaman I've met says some version of this. The ones claiming the title outright are almost always the ones to avoid. His partner translated from Spanish into English. They explained what the medicine does and doesn't do, what to expect physically, what might come up emotionally, and what they would do if someone struggled. They told us bluntly: the body can feel heavy. The body can feel orgasmic. The ego dissolves. You may not remember who you are. They asked each of us to set an intention. People went one at a time. Raul would load the pipe, heat it, and guide the person to breathe out, then inhale slowly and hold. Within seconds, most of them either lay back voluntarily or were gently lowered to the floor. Then came the next fifteen or twenty minutes — completely different for everyone. Some people went silent and motionless. One person sobbed. One laughed for nearly the entire time. One thrashed for two minutes and then went still and beatific. Raul's response shifted with each — sometimes singing, sometimes waving a feather, sometimes just sitting nearby looking unbothered. There was no formula. He read each person and responded. What surprised me, watching, was how unlike kambo this looked. Kambo is loud — the racing heart, the purging, the heat. Bufo was quieter on the outside. The whole drama was happening internally. That calmed me down a little before my turn. When they called me up, my main fear wasn't death itself. It was leaving my kids without a mother. But everyone in the circle had returned from their own dying, so I figured I could too. I'd later come to think of that moment — the willingness to let go even briefly — as the actual work. The smoke is just the vehicle. The pipe touched my lips. It tasted like singed hair and something organic I'd rather not name. I relaxed my throat and kept drawing it in until Raul said stop. Hold. The drop was immediate. I felt myself fall backward into the floor — into the earth beneath the floor — while a warm, overwhelming light filled my visual field. Behind my eyelids, fractals rushed toward my forehead at speeds I had no reference for. Most were drenched in color. Some were stark black and white. Waves of sensation moved through me that I genuinely have no language for. So this, I thought from somewhere, is what dying feels like. What I learned in those minutes — and this is the only practical thing I can really offer you — is that resistance and surrender produce wildly different experiences inside the same medicine. When my thinking mind tried to assert itself (should I make sounds? should I move?) the colors dimmed and a harsher, more judgmental texture crept in. When I let go and dropped attention back into the fractals, the beauty returned. The choice point was right there, over and over. That's the practice. I sat up, eventually. Raul was in front of me. We held eye contact for what felt like a long, wordless conversation. My mind was already running its usual program — did I do that right? what now? — but underneath it was a quieter knowing that didn't need anything from me. We bowed. He leaned in and said one word in my ear that happened to be the exact word I'd been working with all year. I won't share it. It would mean nothing to you and everything to me. For about a week, I felt soft and porous in the best way. More love in my chest. Easier tears at small things — strangers laughing on a tram, my kid drawing something terrible and showing me proudly. Also, oddly, the world felt slightly flat. The colors of ordinary life were duller, as if I now knew about a dimension that wasn't currently accessible. This is normal. Integration after 5-MeO-DMT can include a kind of homesickness for the state the medicine showed you. Some people report a low or grey period in the second or third week. Some get the opposite — sustained joy, clarity, a quieter inner critic. Most get some of both. If you're thinking about sitting with Bufo, plan your calendar accordingly. Don't book a ceremony the night before a job interview or a wedding you have to host. I can't answer that for anyone else. What I can say is that Bufo is not a beginner medicine, and it's not a substitute for therapy, recovery work, or the long slow building of a life you actually want to be in. It's a brief, extraordinary look at something — call it consciousness, call it presence, call it whatever you want — and what you do with that look is the rest of the work. If you're drawn to it because ayahuasca felt too long, kambo too physical, or psilocybin too narrative — fair enough. If you're drawn because you want a shortcut past your trauma, please reconsider. There are no shortcuts. The medicine can crack open a door; walking through it is still on you. For readers who feel quietly called to take this further, a curated selection of 5-MeO-DMT and broader plant-medicine retreats can be browsed on our marketplace here. Take your time choosing. The right ceremony will still be there when you're ready.
When Clergy Take Psilocybin: Inside the Mystical Experience Study
A rabbi, a Greek Orthodox priest, and a Zen roshi walk into a research lab. No punchline. They drink a measured dose of psilocybin, lie back on a couch with eyeshades on, and spend the next six hours somewhere most of us will never go without a guide. This actually happened. It's still happening, in fact, as researchers at Johns Hopkins and NYU continue to study what happens when people who have spent their entire adult lives cultivating spiritual experience meet the compound in magic mushrooms head-on. The study is one of the strangest, most fascinating threads in the current wave of psychedelic research — and for anyone weighing whether plant medicine or psychedelics might be worth exploring personally, it's worth understanding why scientists felt the need to recruit clergy in the first place. Here's the puzzle that's been bugging psychedelic researchers for a decade. Psilocybin reliably does something to depression, end-of-life anxiety, and addiction that conventional medicine struggles to replicate. People who undergo a single, well-supported session often describe lasting shifts — less fear, more connection, a softened grip on whatever was strangling them before. The clinical results are real. The mechanism is murky. What participants keep saying, over and over, is that the session contained a “mystical” or “deeply meaningful” experience. Not a hallucination. Not a fun trip. Something closer to what contemplatives across traditions have described for thousands of years — ego dissolution, a felt sense of unity, encounters with what people variously call God, source, presence, or simply love. Roland Griffiths, the Johns Hopkins psychiatrist who pioneered much of this research, has noted that healthy volunteers with no prior psychedelic experience routinely rank their psilocybin session among the most spiritually significant events of their lives. Up there with the birth of a child. That's a wild claim coming out of a pharmacology lab. And it raised an obvious question: if these experiences resemble what mystics have been reporting since before recorded history, why not ask actual mystics to weigh in? The trial enrolled religious leaders from across traditions — an Orthodox rabbi, an Episcopalian, a Greek Orthodox priest, a Zen Buddhist roshi, a Reform Christian minister, among others. Researchers were also seeking Catholic priests, imams, and Hindu priests. Each participant receives psilocybin in a carefully controlled setting: comfortable room, trained monitors, music, eyeshades, the works. The protocol is the same one that's been used with cancer patients and people struggling with treatment-resistant depression. The difference is what comes after. These participants don't just fill out a questionnaire. They use the vocabulary and frameworks of their own traditions to describe what they encountered. A Zen practitioner can speak the language of emptiness and form. A Christian minister can speak about grace, presence, the felt nearness of the divine. Researchers compare notes across traditions and against the clinical data, looking for patterns. The hope is that people who have spent decades parsing subtle spiritual states can help science build a better map of what psilocybin actually does to consciousness — and why that mapping seems to translate into durable mental-health benefits. The full study results are still being analyzed, but early signals are striking. Anthony Bossis, who runs the NYU arm of the trial, has said that several of the clergy entered the study in a state of professional burnout — that particular hollowed-out feeling that comes from years of holding space for other people's suffering. After their sessions, many described something like renewal. Increased passion for their work. A re-quickened relationship with scripture. More energy for the people in their care. If those changes hold up over time, they echo what's been seen in other psilocybin trials: a small number of sessions seem to produce shifts that persist for months or years. Not a quick fix. More like a re-orientation. One thing worth noting honestly: not every participant has a peak experience, and not every peak experience is pleasant. Some sessions involve fear, confrontation with difficult material, what researchers diplomatically call “challenging experiences.” The trained monitors are there for exactly this reason. Anyone telling you psychedelics are uniformly blissful is selling something. You might be reading this because you're researching a psilocybin or ayahuasca retreat for reasons that have nothing to do with academic curiosity. Depression that won't budge. A drinking problem you've tried to white-knuckle. Grief. A sense that your life has gotten stuck in a groove you can't climb out of. Many people who end up in ceremony arrive carrying exactly that kind of weight. The clergy study is relevant to your decision in a few practical ways: There's something almost funny about watching elite American universities rediscover what shamanic traditions have known forever — that psilocybin mushrooms, ayahuasca, peyote, and other plant medicines occupy a category that's irreducibly spiritual. Strip out the spiritual frame and you get a pharmacological curiosity. Keep it in, and you have a tool that's been used for healing, vision, and community repair across cultures for as long as humans have been paying attention. The Mazatec curanderos of Oaxaca knew this about mushrooms. Shipibo healers in the Peruvian Amazon know it about ayahuasca. Bwiti practitioners in Gabon know it about iboga. The compounds are chemistry, but the work is something else — call it mystical, call it psychospiritual, call it what your tradition calls it. The clergy study is one of the first serious attempts in modern Western science to take that work on its own terms. For someone considering a retreat, that's worth absorbing. You're not signing up for a recreational experience or a wellness perk. You're stepping, however briefly, into a lineage that the world's contemplatives have been walking for a very long time. Treat it accordingly. Choose facilitators who do the same. Plant medicine and psychedelics are not for everyone. People with personal or family histories of schizophrenia, bipolar I, or certain other psychiatric conditions face real risks. Some SSRIs and other medications interact dangerously with ayahuasca in particular. The legal landscape varies wildly — psilocybin is decriminalized or therapeutically available in a handful of jurisdictions, illegal in most. Ayahuasca occupies a gray zone almost everywhere outside its traditional South American home. And honestly, even when everything goes well, plant medicine tends to ask more of you than it gives upfront. The reorganization people describe afterward is real, but it asks for follow-through. New habits. Hard conversations. Sometimes leaving jobs or relationships that no longer fit. The clergy in the study had spiritual scaffolding to lean on. If you don't, build some before you go. If any of this has stirred something — curiosity, recognition, the quiet sense that it might be time — a curated selection of psilocybin and plant-medicine retreats can be explored on our marketplace here. Take your time choosing. The good ones are worth the search.
Why Silicon Valley Money Is Pouring Into Psychedelics Startups
Something strange is happening at the intersection of psychedelics and Silicon Valley. The same investors who funded scooter apps and food-delivery platforms are now writing checks to companies developing the next generation of psychedelic-assisted therapies. If you'd told me a decade ago that the world's most famous startup accelerator would be backing magic-mushroom research, I'd have laughed into my mug of mapacho tea. And yet here we are. Analysts have floated numbers north of $100 billion for the future psychedelics market, and the money is moving accordingly. For anyone researching ayahuasca, ibogaine, psilocybin, or other master plants — whether for addiction recovery, depression, or just the kind of stuck life pattern you can't seem to shake — this matters. The infrastructure behind plant medicine is changing fast, and what gets built (or doesn't) over the next five years will shape the retreats, clinics, and protocols you'll eventually choose between. The short answer: clinical results, decriminalization momentum, and an addiction-and-depression crisis that mainstream pharma hasn't dented. SSRIs have plateaued. Opioid overdoses keep climbing. Veterans are dying by suicide at rates that should embarrass everyone. Into that vacuum walks a body of research — much of it from Johns Hopkins, NYU, Imperial College London, and MAPS — suggesting that compounds like psilocybin, MDMA, and ibogaine produce meaningful, sometimes durable improvement after just one or two sessions. Investors smell a fundamental shift. Not incremental. Generational. When something works better than the current standard of care and the regulatory door is creaking open, capital floods in. That's the boring, predictable part. The interesting part is what those investors choose to fund. The famed Y Combinator accelerator — the one that backed Airbnb, DoorDash, and Dropbox before anyone knew their names — has quietly admitted several psychedelics companies to its program. A spokesperson was careful to say YC doesn't pick industries, it picks teams. Fair enough. But the fact that four psychedelics startups cleared a roughly 1.5% acceptance bar tells you something about where smart money thinks the puck is heading. A handful of YC-backed companies give a useful snapshot of the space. None of them run retreats. All of them are building the scaffolding around the medicines themselves. What's striking is the range. One company is building clinical software. Another is doing computational drug design. A third is running traditional pharma R&D with a psychedelic twist. None of them are running ceremonies in the jungle. That distinction matters more than it might seem. Here's where things get philosophically interesting, and where I'll be honest about my own bias. I've sat in ayahuasca ceremonies. I've watched people work through grief, trauma, and addictions that years of talk therapy hadn't budged. The thing that made those experiences powerful wasn't the molecule alone — it was the container. The shaman who knew when to sing and when to be silent. The dieta beforehand. The integration circle the next morning. The jungle itself. Venture-backed psychedelics is a different beast. It's optimized for FDA approval, insurance reimbursement, and scalable clinical delivery. That has real upside: standardized dosing, medical oversight, fewer cowboys offering "ceremonies" in suburban living rooms. It also has real costs. The ceremonial context — the lineage, the songs, the relationship with the plant as a being and not a compound — doesn't fit neatly on a Series A pitch deck. For readers weighing whether to fly to Peru, Costa Rica, or Mexico for a traditional retreat versus waiting a few years for a clinical option closer to home, the trade-offs are worth thinking about honestly: None of these paths is automatically right. What matters is matching the path to what you're actually working with. Someone with treatment-resistant depression and no trauma history might do beautifully in a clinical setting. Someone unwinding decades of complex PTSD or wrestling with addiction often needs the longer arc and ceremonial holding that retreats provide. A hundred billion dollars sounds like it could solve a lot of problems. It won't solve the ones that matter most. It won't teach a facilitator how to sit with someone in their darkest hour without flinching. It won't replicate the apprenticeship of a curandero who learned from their grandmother who learned from hers. It won't undo the extractive history of foreign companies patenting compounds that indigenous people have used for generations. And — this is the quiet part nobody at a pitch meeting wants to say — it won't change the fact that psychedelic healing is hard, often uncomfortable, and absolutely not a shortcut. I've seen people come back from a retreat changed in ways that lasted years. I've also seen people come back convinced they were healed, then quietly relapse six months later because they skipped the integration work. The medicine is not the cure. The medicine cracks something open, and then the actual work begins. No amount of venture funding changes that math. Both. Probably more good than bad, if I'm being fair. Legalization and clinical access mean people who would never travel to the Amazon — veterans, people with chronic illness, people without passports or PTO — will eventually get access to compounds that could genuinely help them. That's worth a lot. The risk is monoculture. If clinical models dominate the conversation, the ceremonial traditions get framed as quaint, unscientific, or unsafe — even when they've been refined over centuries and produce outcomes the studies are only beginning to measure. The best future is one where both exist, where someone can choose a six-day ayahuasca retreat with a vetted lineage or a structured psilocybin protocol at a clinic forty minutes from home, depending on what they need. For readers who want to take this further, a range of curated plant-medicine and psychedelic retreats can be browsed on our marketplace here — useful if you're weighing the traditional side of the equation against the clinical wave that's still a few years out. Whichever path you find yourself drawn to, do the homework. Talk to people who've sat with the specific medicine you're considering. Ask facilitators uncomfortable questions about training, safety protocols, and what happens if something goes wrong. The money rushing in will eventually make this whole landscape safer and more accessible. Until it does, your discernment is the most valuable thing in the room.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
Microdosing Psychedelics for Focus and Creativity: What's Really Going On
Somewhere between the third coffee and the Sunday-night dread, a quiet question has started showing up in group chats and on private Substacks: is microdosing actually doing something, or are these people just unusually disciplined about their sleep? The trend has crept out of the Bay Area and into ordinary lives — teachers, lawyers, recovering workaholics, people in their fifties who haven't touched anything stronger than wine since college. Psychedelics, in tiny sub-perceptual doses, have become an open secret. This isn't a sales pitch for it. It's a walk through what the practice actually is, what the (still limited) research says, who tends to benefit, who probably shouldn't bother, and how the whole conversation connects to the broader world of plant medicine and psychedelic healing. If you're researching this because you're stuck — in a job, a mood, an addiction, a relationship pattern — you deserve specifics, not vibes. A microdose is a fraction of a recreational dose — usually somewhere between a tenth and a twentieth. The point is to feel almost nothing. No visuals, no ego dissolution, no giggling at the carpet. The two most common substances are psilocybin (dried mushrooms, typically around 0.1–0.3 grams) and LSD (around 5–15 micrograms). DMT and mescaline get mentioned occasionally but are less practical for daily use. People follow protocols. The best known is the Fadiman protocol — one day on, two days off, repeated for a month or two, then a break. Others go every other day, or Monday/Wednesday/Friday. The schedule matters because tolerance builds quickly with classic psychedelics, and the days off are when most users report the lingering benefits. One thing worth saying clearly: these substances remain illegal in most countries, including most of the United States. A handful of jurisdictions — Oregon, Colorado, certain cities — have begun decriminalizing or regulating psilocybin in specific contexts. The legal picture is shifting, but it hasn't shifted as much as the headlines suggest. The reasons I hear most often, in roughly descending order: Founders and engineers tend to get the press, but the population of people microdosing now is far broader than that. Parents in their forties working through burnout. Veterans cautiously experimenting with their PTSD. Recovering drinkers using it (sometimes alongside therapy) to soften the edge of early sobriety. Here's the honest part: a lot of what's reported is also placebo, and the placebo isn't necessarily a bad thing — it's just not magic. A 2021 study from Imperial College London compared people microdosing psilocybin with people who only thought they were. Both groups felt better. The differences were small. That doesn't mean microdosing does nothing; it means we don't yet have the clean data to say what it does beyond expectation effects. If you've found your way to this article, you're probably also reading about ayahuasca, ibogaine, psilocybin retreats, and the broader category of master plants. It's worth understanding how microdosing relates to those — because they're often discussed together but they do quite different things. A full ayahuasca ceremony, or a high-dose psilocybin session in a clinical or retreat setting, is a discrete event. You sit with it for hours. You may meet something inside yourself that you've been avoiding for twenty years. The work is intense, often uncomfortable, and the integration afterward can take months. People who go deep with master plants typically describe one or two ceremonies as more impactful than years of therapy. Microdosing is the opposite shape. It's a daily-life intervention. You take a tiny amount, you go to work, you make dinner, you talk to your kid about their math homework. The changes — if they come — accumulate slowly and feel like small adjustments in temperament. Some people find this more useful than the big ceremonial work. Others find it doesn't touch the root of what they're carrying, and they end up booking a retreat anyway. Many do both: microdose between ceremonies as a way of staying in dialogue with what came up. The intersection of psychedelics and addiction recovery is where the most genuinely exciting research is happening. Johns Hopkins, NYU, and several European universities have run trials using psilocybin for tobacco cessation and alcohol use disorder, with results that — while early — outperform most existing treatments. Ibogaine, a far more intense plant medicine, has a long underground track record with opioid dependence; people fly to Mexico or Costa Rica for ibogaine treatment when nothing else has worked. Microdosing is a softer tool, and I want to be careful here. If you're in active addiction, microdosing on your own is not a treatment plan. It's a supplement at best and a distraction at worst. The people who've used small doses successfully in recovery almost always have something else in place — a therapist, a support group, a clear protocol, sometimes a residential program that included a higher-dose psychedelic experience as the actual turning point. The pattern I see again and again: a single significant ceremony (ayahuasca, psilocybin, ibogaine, sometimes San Pedro) creates a window of clarity. Microdosing helps keep that window open while the person rebuilds the rest of their life. The ceremony alone fades. The microdose alone may not be enough to break through. Together, with real human support, the combination has changed lives. This part doesn't get said enough. For many people researching microdosing, the underlying question isn't really about microdosing at all. It's: am I willing to do something bigger? A retreat — psilocybin in Jamaica, ayahuasca in Peru or Costa Rica, ibogaine in Mexico — is a substantial commitment of money, time, and emotional bandwidth. It also tends to produce results that microdosing alone won't. If you're at that crossroads, a few honest things to weigh: what you're hoping to address, whether you have integration support available afterward (this matters more than the ceremony itself), the reputation and lineage of the facilitators, and whether the center is upfront about screening for medical and psychiatric contraindications. Any retreat that doesn't ask thorough medical questions before accepting you should be a hard pass. For readers who want to take this further, a curated selection of psychedelic and plant-medicine retreats can be browsed on our marketplace here. Whether you end up booking one or not, reading through what's actually offered — the durations, the protocols, the aftercare — is one of the better ways to understand what serious psychedelic healing looks like in practice. The decision to work with psychedelics, in any dose, is personal and worth taking slowly. Curiosity is healthy. Hype is not. Trust the version of yourself that's still asking questions.
Inside the Rise of Luxury Psilocybin Retreats: What You Actually Get for $7,000
Somewhere between the wellness spa weekend and the underground ceremony in a friend-of-a-friend's basement, a new category has quietly taken shape: the luxury psilocybin retreat. Five-figure flights aside, you're now looking at programs in Jamaica, Costa Rica, and the Netherlands that charge anywhere from $3,900 to nearly $7,000 for a week, mushrooms included. The clientele isn't who you'd expect either. It's lawyers, founders, surgeons, mid-career people who've quietly read every Michael Pollan paragraph twice and want to know what the fuss is about — in a setting where nobody is going to call the cops. I've spent enough time around plant medicine and psychedelic spaces to feel both excited and twitchy about this trend. On one hand: more people getting access to real psychedelic healing, in safer settings, with proper integration. That's progress. On the other hand: a lot of money is flooding in, and not all of it is arriving with clean intentions. So let's actually look at what these retreats offer, what they cost, and whether you — sitting there reading this, weighing whether to spend the equivalent of a used car on a week with mushrooms — should consider one. The shorthand is easy: a multi-day program at a private property, usually in a jurisdiction where psilocybin sits in a legal grey or green zone, with screened participants, trained facilitators, and a ratio of staff to guest that would make most yoga retreats jealous. The longer answer is more interesting. These programs are designed less like a vacation and more like a structured therapeutic arc — preparation, ceremony, integration — wrapped inside the trappings of a five-star stay. What you're really paying for is the container. A villa with thirteen rooms tucked away on a river, two pools, organic meals, a maloca or ceremony space that doesn't smell like the last guy's cologne. One facilitator for every three or four guests. Pre-retreat coaching calls. Six weeks of group integration after you've gone home and your boss is wondering why you keep crying during meetings. That's the product. The mushrooms, ironically, are maybe a third of it. Here's where I have to be honest with you, because the entire psychedelic retreat space is starting to develop the same uncomfortable rhetoric the wellness industry mastered years ago — the implication that if you really want to heal, you'll find the money. I don't buy it. Plenty of people have had transformative psychedelic experiences for the cost of a tank of gas. The mushroom doesn't know what you paid for it. What the money actually buys you is risk reduction and follow-through. Specifically: If you have $7,000 and you'd otherwise be eating mushrooms alone in your apartment on a Tuesday, the retreat is probably the better bet. If $7,000 means second-mortgaging something or canceling a year of therapy to afford it, that math gets ugly fast. There are quieter, smaller, more affordable options out there — including community-based circles in legal jurisdictions and lower-cost retreats in Mexico and Jamaica. The luxury version is one tier of a wider menu, not the only entry point. Most reputable luxury retreats are explicit that they're not designed for people in acute mental health crisis. The phrase used inside the industry is "healthy normals" — people whose lives function, who aren't actively suicidal or in psychotic territory, but who feel stuck. Numb. Career on autopilot, marriage on autopilot, evenings disappearing into a glass of wine and a screen. That kind of stuck. These programs also screen for harder stuff: family history of schizophrenia, current medication conflicts, recent major loss. If you're carrying severe trauma or you're in recovery from substance dependence, a generic luxury retreat may not be the right room for you. Ibogaine programs, dedicated trauma-informed psilocybin therapy, or ayahuasca centers with strong medical staff are different animals built for different work. Don't let glossy marketing convince you a five-star villa is equivalent to a clinical setting — it isn't. The honest reader profile, in my experience, looks like this: late thirties to mid-fifties, professionally accomplished, has read at least one psychedelic book, hasn't tripped since college (if ever), wants the experience inside a setting that feels grown-up and safe. If that's you, the luxury retreat category is genuinely built around your nervous system. The structure across reputable programs is remarkably similar, which is reassuring — it suggests the practitioners are talking to each other and converging on what works. A typical arc: Notice how little of that is the trip itself. Maybe twelve hours out of a hundred-and-twenty-hour program. The rest is scaffolding — the thing that determines whether your six hours of altered consciousness becomes a permanent shift or a fading memory you'll bring up at dinner parties for the next year. Not every retreat charging luxury prices is delivering luxury care. As money has poured into the psychedelic space, I've watched programs spring up that are essentially weekend parties dressed in shamanic costume. A few things to look for, and look out for: The good operators welcome scrutiny. They'll send you their facilitator bios, walk you through the medical screening, and tell you who they've turned away and why. If a program won't engage with those questions, your wallet has its answer. The psychedelic retreat industry is growing fast — projections for the broader psychedelic medicine market run into the tens of billions over the next decade. Regulation is shifting too, with Oregon and Colorado already operating legal psilocybin therapy frameworks and several other states inching that direction. The FDA hasn't approved psilocybin for general therapeutic use yet, but clinical trials for depression and end-of-life anxiety have produced results compelling enough that approval feels like a question of when, not if. What this means practically: in five years, the $7,000 luxury retreat in Jamaica may have local equivalents at a fraction of the price. Community-based psilocybin centers, insurance-covered clinical sessions, lower-cost retreats with the same quality of care. The current premium reflects scarcity and legal complexity more than the underlying value of the mushroom or the work. If cost is the only thing keeping you from exploring this, the menu is widening every year. That said, the work itself isn't going to get any easier just because the price drops. Psychedelics aren't a shortcut — they're an accelerant. They show you what's there. The discipline of integrating what they show you, of actually changing the patterns they illuminate, is still on you, retreat or no retreat. The honest answer depends on what you're after. If you're a curious, reasonably healthy person who wants to explore psilocybin in a setting designed not to traumatize you, and you can afford it without financial strain, a well-run luxury retreat is one of the safest, most supported ways to do that work right now. If you're carrying heavier stuff — addiction, severe trauma, treatment-resistant depression — you want a program built specifically for that, not a wellness retreat dressed up as therapy. And if you've read this far and something in you is leaning toward yes, take that seriously. Curiosity that persists past the second article is usually pointing somewhere. For readers ready to look at specific options, a range of vetted psilocybin retreats can be browsed on our marketplace here. Take your time with the choice. The right container matters more than the right price tag.
Microdosing Iboga for Dopamine Issues: What You Should Actually Know
Microdosing iboga is one of those topics that lives in the gap between forum gossip and actual clinical research. People whisper about it. A few swear by it. Most have no idea what they're talking about. And yet, if you spend any time in the corners of the internet where folks discuss addiction recovery, ADHD, depression, or the strange flatness that follows years of stimulant use, you'll hear iboga root bark mentioned — usually in tones that mix awe with a healthy dose of caution. Let's talk about what microdosing iboga actually involves, why dopamine sits at the center of the conversation, and what someone considering this path should think hard about before they start. This is plant medicine territory, and iboga is not a substance to treat casually — even at small doses. Iboga (Tabernanthe iboga) is a shrub native to West Central Africa, mostly Gabon and Cameroon, where the Bwiti tradition has used it ceremonially for generations. The root bark contains a family of alkaloids, the most famous being ibogaine — the compound that's made headlines for its ability to interrupt opioid and stimulant addictions, sometimes in a single high-dose session. A full ibogaine flood dose is intense. We're talking 12 to 36 hours of waking dream-state, deep autobiographical review, and significant cardiovascular load. That's the version you see at clinics in Mexico, Costa Rica, and increasingly other jurisdictions. Microdosing is something different: people take small amounts of root bark — often 100 to 300 milligrams — with the goal of subtle, sub-perceptual effects over weeks or months. The motivations vary. Some are stacking it onto recovery from opioid or stimulant addiction, hoping to keep cravings quiet between flood sessions. Others are dealing with post-acute withdrawal, where dopamine receptors are sluggish and motivation has gone missing. A smaller group is experimenting with iboga the way people experiment with psilocybin microdosing — for mood, focus, or what they vaguely call “stuckness.” If you've burned through your dopamine system — years of cocaine, methamphetamine, heavy stimulant prescriptions, or even just compulsive screen and porn use — you might find yourself in a strange flat zone. Nothing feels rewarding. You can't get yourself to start anything. Pleasure feels theoretical. This is the territory where people start researching iboga. Here's what's interesting: ibogaine and its primary metabolite noribogaine appear to act on the dopamine system in unusual ways. Rather than flooding receptors like an amphetamine, they seem to modulate — interacting with sigma-2 receptors, NMDA receptors, and various dopamine and serotonin pathways simultaneously. Animal studies have shown that ibogaine can help normalize dopamine signaling after chronic stimulant exposure. That's not a guarantee for humans, but it's why the substance keeps showing up in conversations about addiction recovery and post-stimulant burnout. The honest answer to “does microdosing iboga restore dopamine function?” is: we don't really know. There's anecdote, there's mechanistic plausibility, and there's almost no rigorous clinical data on the microdose protocol specifically. Most of the published research is on flood doses for addiction interruption. Anyone who tells you the science is settled here is either selling you something or hasn't read enough of it. Iboga is not psilocybin. It is not LSD. The safety profile is genuinely different, and this is where a lot of well-meaning people get themselves into trouble. The main issue is cardiac. Ibogaine prolongs the QT interval, which in plain terms means it can disrupt the heart's electrical rhythm in ways that have, in rare cases, been fatal. The risk goes up dramatically if you have: At microdose levels the risk is lower than at flood-dose levels — but it's not zero, especially with repeated daily dosing that allows ibogaine and noribogaine to accumulate. Noribogaine has a long half-life. The drug stays in your system. This is why anyone serious about exploring iboga, even at low doses, gets bloodwork and an EKG first. Not optional. Not paranoid. Standard practice. From what people who've done it describe, a true microdose of iboga root bark is subtle. Some report a slight warming sensation, mild stimulation, easier focus, and a kind of quiet emotional steadiness. Others get nothing. A handful overshoot the dose and end up with nausea, ataxia (that wobbly, drunk-feeling coordination loss iboga is known for), and a tracer-laden visual field that's well past sub-perceptual. The bark itself is unforgivably bitter. People who've worked with it say the taste is genuinely difficult — like chewing aspirin mixed with damp earth. Capsules help. Most experienced practitioners suggest starting much lower than you think you need to, waiting a full day to see how your body responds, and never dosing daily without breaks. A common protocol you'll see discussed: small dose two or three times per week, with rest days in between, for a defined period — maybe four to eight weeks — followed by a longer break to assess what's actually changed. Daily dosing is where accumulation risks rise and where people start running into trouble. If you're reading this because you're stuck — addicted, depressed, exhausted by your own patterns — please hear this clearly: microdosing iboga off the back of a Reddit thread, alone, with no medical screening and no integration support, is not a recovery plan. It's a gamble with a substance that deserves more respect than that. What does a reasonable approach look like? Usually some version of: Iboga sits in an interesting place in the master plants family — alongside ayahuasca, San Pedro, and peyote — as a teacher plant with a long traditional lineage. Treating it like a nootropic supplement misses the point and creates real risk. For readers who want to explore this more seriously, a range of ibogaine and iboga retreat programs with medical screening and trained facilitators can be browsed on our marketplace here. The dopamine question, the addiction question, the “am I broken?” question — these are real, and plant medicine can sometimes be part of an answer. Just not a shortcut, and not without the work that surrounds it.
Microdosing Psychedelics at Work: What the Science Actually Says
A few years back, the CEO of a marketing startup got fired for taking a tab of LSD before a company meeting. Not a recreational dose — a sliver, what people in certain circles call a microdose. He said it would sharpen his focus. The board said it violated company policy. The internet, predictably, lost its mind for about forty-eight hours and then moved on. But the question underneath that story hasn't gone anywhere. Does microdosing psychedelics actually do what people claim it does? Is it a legitimate cognitive tool, a placebo with great PR, or just an expensive way to get on the wrong side of the law? If you're reading this, you've probably wondered. Maybe a friend swears by it. Maybe you've read a profile of a founder who credits LSD with their breakthrough. Maybe you're curious whether the same compounds being studied for depression and addiction might quietly help you, too. Here's what the research actually shows, what experienced clinicians say, and why the relationship between microdosing and the deeper work of plant medicine is more interesting — and more honest — than the workplace-hack version of the story. A microdose is a sub-perceptual dose. That's the technical definition. You take roughly a tenth of what a recreational user would take — somewhere around 10 to 20 micrograms of LSD, or 0.1 to 0.3 grams of dried psilocybin mushrooms — at intervals over weeks or months. The idea is that you feel almost nothing. No visuals, no ego dissolution, no cosmic download. Just a faint shimmer underneath your normal day. People who microdose report better mood, more creative thinking, sharper focus, an easier time meditating, and reduced anxiety. Those are the claims. The protocol most often cited — one day on, two days off — comes from psychologist James Fadiman, who's been writing about this since the 1960s. He's the godfather of the whole movement, and he's also remarkably measured about what he thinks it does. What microdosing is not is a psychedelic experience. You don't journey on a microdose. You don't confront your shadow or meet ancestors or weep through twenty years of unprocessed grief. That's macrodose territory — heroic doses, as researchers call them — and it's a fundamentally different thing. Conflating the two is one of the more common mistakes people make when they start reading about this stuff. Short answer: not really. Not yet, anyway, and possibly not at all in the way enthusiasts hope. The most rigorous study to date, published a few years ago in eLife, ran a self-blinded trial where participants took either real microdoses or placebos. Both groups reported improvements in mood, energy, and cognition. The catch? The improvements were essentially identical. The active-dose group didn't outperform the placebo group in any meaningful way. The researchers' polite conclusion was that the reported benefits of microdosing appear to be largely placebo-driven. That's not nothing. Placebos are powerful. If taking a tiny dose of something exotic makes you believe you'll be sharper and calmer, you probably will be sharper and calmer for a while, because expectation shapes experience. But you can get the same effect from a daily ritual, a multivitamin, or — if we're being honest — a decent cup of coffee. Researchers at Johns Hopkins, who run the most established psychedelics program in the country, have been blunt: the strong evidence for psychedelics as a therapeutic tool lives almost entirely at the high-dose end. The benefits don't seem to scale down. If anything works at microdose levels, it's most likely a mild antidepressant effect from nudging the serotonin system — which is also exactly what SSRIs do, with fewer legal complications and decades more safety data. The tech industry's romance with microdosing isn't really about the pharmacology. It's about the story. Steve Jobs famously called taking LSD one of the most important experiences of his life. Founders trade Fadiman's protocol like a productivity hack. The narrative goes: smart, ambitious people gain an edge by treating their brains like an OS that can be patched and optimized. And look — the underlying impulse isn't crazy. Psychedelics genuinely do something to cognition. People who take real, meaningful doses in well-held settings often describe lasting shifts in perspective, creativity, and emotional flexibility. The mistake is assuming you can get those benefits in tenth-strength increments while still running a 10 a.m. stand-up. You can't, mostly. The actual transformative effects of psychedelics seem to require the full experience — the discomfort, the surrender, the eight hours where you cannot, under any circumstances, lead a meeting. That's not a bug. That's the point. The deep work happens precisely because the usual self is offline. This is the part of the conversation that gets glossed over in glowing founder profiles. LSD, psilocybin, and MDMA are Schedule I substances in the United States. Possessing them is a federal crime. Microdosing at work, the way the Iterable CEO learned, can also end your career fast — even in companies that consider themselves enlightened about substance use. Then there are the practical issues. When you're sourcing tabs or mushrooms from someone you met through a friend of a friend, dose accuracy is a fantasy. People aim for 15 micrograms of LSD and accidentally take 80. Suddenly the wall is breathing during a budget review. Researchers have heard versions of this story more times than they care to count. Some honest concerns to sit with if you're considering this: If you've gotten this far, you might be sensing the more interesting question underneath all this. People aren't microdosing because they want to optimize quarterly OKRs. Most of them are quietly hoping for something deeper — relief from depression, a way out of an addiction, a softening of trauma, a sense that there's more to life than the loop they've been running for fifteen years. That's the territory where psychedelics genuinely shine, and it's not microdose territory. Clinical trials with psilocybin for treatment-resistant depression have produced results that legitimately surprised the researchers. Ibogaine has helped people walk away from opioid dependency in ways nothing else has. Ayahuasca ceremonies, conducted in traditional contexts with experienced facilitators, have given people decades of stuck patterns to chew on in a single night. These are the master plants — substances that traditional cultures have worked with for generations, in settings designed to hold the weight of what they bring up. The honest framing is this: a microdose is a hack. A retreat is a reckoning. They're different tools for different jobs. If what you actually want is a slightly better Tuesday, drink a coffee and go for a walk. If what you want is to look honestly at why your Tuesdays feel the way they do — that's a different conversation, and it probably involves a real dose, a real container, and people who know what they're doing. The thing about psychedelic healing — the real thing, not the productivity version — is that it works in the opposite direction from optimization. It asks you to slow down, not speed up. It rewards surrender, not control. The Silicon Valley pitch of move-fast-and-break-things is almost exactly the wrong posture for the work. People who come out of a well-run retreat tend to describe months of integration afterward. Slow re-entry. Conversations with a therapist or guide. Changes that show up not as a sudden flash of insight but as a different relationship to their own habits over time. None of that fits in a microdose protocol. None of it shows up in a single ceremony, either — the integration is the medicine, in many ways. If you're weighing whether this path makes sense for you, take your time. Read accounts from people who've done it. Ask hard questions about lineage, safety screening, and what happens if something difficult comes up in ceremony. The good operators welcome those questions. The sketchy ones don't. For readers who want to explore this more seriously, a range of vetted ayahuasca, psilocybin, and other plant-medicine retreats can be browsed on our marketplace here. It's a quieter and more considered route than the workplace microdose — and, by most accounts of the people who've actually done both, a far more useful one.
Why Venture Capital Is Skeptical About Oregon's Legal Psilocybin Market
Oregon did something genuinely historic when it voted to create the first state-regulated psilocybin program in the country. For anyone interested in psychedelics, plant medicine, or the slow drift of mushrooms out of the underground and into licensed spaces, it was a moment worth marking. So you'd assume the venture capital crowd — the same people pouring tens of millions into psychedelic startups — would be lining up at the border with checkbooks open. They're not. Several of the most active investors in the psychedelics space have quietly made it clear they're skipping Oregon, at least for now. Their reasoning is worth understanding, because it tells you something useful about where this whole industry is heading — and what it might mean for the kind of retreat experience you can actually book in the years ahead. Measure 109 created a framework where adults can take psilocybin under the supervision of a licensed facilitator at a licensed service center. It's not medical. It's not recreational. It's a third thing — call it supported use — and it sits inside a single state while psilocybin remains a Schedule I substance at the federal level. That last detail is doing a lot of heavy lifting in this story. The companies preparing to operate in Oregon are mostly retreat centers, training programs for facilitators, and small clinic-style operations. Some are familiar names in the psychedelic retreat world — outfits that have spent years running ceremonies in places like the Netherlands or Jamaica and now want a foothold inside the United States. On paper, it looks like the beginning of a real market. Talk to people running psychedelic-focused venture funds and a few specific objections come up again and again. None of them are about whether psilocybin works. They're about whether a business built around it can make money under the rules as written. The first issue is taxes. Because psilocybin is federally illegal, businesses handling it get hit by the same IRS provision — Section 280E — that has been making life miserable for cannabis operators for years. In plain English: you can't deduct normal business expenses like rent, payroll, or marketing the way an ordinary company can. Your effective tax rate balloons. Margins that already look thin get sliced even thinner. The second issue is the math of a single session. A ketamine clinic — currently the closest legal comparison in the US — can move a patient through treatment in roughly an hour or two. A psilocybin session runs significantly longer; six hours is a reasonable baseline once you add preparation and the come-down. That's one room, one facilitator (sometimes two), one client, for most of a working day. Even at premium pricing, the unit economics get tight fast. The third issue is scale. Venture capital looks for businesses that can grow ten or a hundred times larger with an injection of cash. A retreat center on a 124-acre property in southern Oregon is a beautiful thing. It is not, in the VC sense, scalable. You can't ship it. You can't 100x it. You can open a second one, eventually, and that's about it. The money is mostly flowing somewhere else: toward biotech companies running clinical trials on psilocybin, MDMA, and related compounds, hoping to get them approved as prescription medicines through the FDA. If that approval comes — and several late-stage trials suggest it might, for conditions like treatment-resistant depression and PTSD — those companies suddenly have a federally legal product, insurance reimbursement, and a defensible patent position. That's a very different business than running ceremonies in a wooden lodge with a facilitator who sings to you for six hours. It's pharmaceutical psychedelics. It's also where most of the venture capital has gone for the past several years, and it explains a lot about the public conversation around psychedelic healing — what gets covered, what gets funded, what gets framed as legitimate. Here's where it gets interesting for the person actually researching whether to sit in a ceremony. The VC cold shoulder toward Oregon isn't necessarily bad news. In some ways it might be the best thing that could happen to the experience itself. When venture money flows in, it brings expectations. Growth targets. Standardized protocols. Pressure to move clients through faster. The retreat world has spent decades being shaped by tradition, by individual facilitators, by lineage, by the slow accumulation of practice. The places that resist quick scaling are often the ones doing the most careful work. That said, there are some practical things worth knowing if you're weighing Oregon as a destination versus going to an established ayahuasca or psilocybin retreat abroad: Most of this VC drama is centered on psilocybin specifically, because that's what Oregon legalized. But it sits inside a bigger conversation about plant medicine as a whole. Ayahuasca, San Pedro, iboga, peyote — what indigenous traditions often call master plants — operate in a legal and cultural space that's even more complicated than mushrooms in Oregon. They're not on the table for state-level legalization in the US anytime soon, and the established retreats for these medicines are almost entirely outside the country. For people seeking help with addiction, depression, or the kind of stuck patterns that talk therapy hasn't budged, the choice often comes down to: wait for a clinical pipeline that may or may not deliver a relevant treatment in five years, try the new Oregon model when it opens up, or travel to an established retreat tradition that has been doing this work for decades or centuries. None of these is automatically the right answer. They're different doors into different rooms. What's clear is that the underground-to-legal transition is messier than the headlines suggest. The investors backing away from Oregon aren't doing it because they think psychedelics don't work. They're doing it because they think the business model is hard. Those are different things, and confusing them leads to bad decisions on both ends — investors missing real opportunities, and seekers assuming that what gets the most funding must be the best path to healing. If you're somewhere in that 22-to-60 bracket of adults quietly looking into this for real reasons — addiction in the family, depression that won't lift, grief that's gone on too long — the most useful thing you can do is ignore the industry noise and ask basic questions of any program you're considering: You won't find these answers in a glossy brochure. You'll find them in long phone calls, honest references, and the willingness of a retreat to talk about hard cases instead of dream testimonials. The legal landscape will keep shifting. Oregon will figure out its market, or it won't. Colorado, which passed its own measure shortly after, will run its own experiment. Federal approval for psilocybin therapy could land within a few years. None of that changes the basic question for the person reading this: is plant medicine the right next step for you, and if so, with whom, where, and when? For readers who want to explore this further with a clearer view of the options, a curated range of ayahuasca and psilocybin retreats can be browsed on our marketplace here. Take your time with the decision. The medicine isn't going anywhere, and the right container is worth waiting for.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
